1	High effectiveness of multimodal infection control interventions in preventing SARS-CoV-2
2	infections in healthcare professionals: a prospective longitudinal seroconversion study
3	
4	Thomas Theo Brehm, MD ^{1,2,#} , Dorothee Schwinge, PhD ^{1,#} , Sibylle Lampalzer, MD ¹ , Veronika
5	Schlicker, BA ^{1,2} , Julia Küchen ¹ , Michelle Thompson ¹ , Felix Ullrich ¹ , Samuel Huber, MD ¹ ,
6	Stefan Schmiedel, MD ^{1,2} , Marylyn M Addo, MD ^{1,2} , Marc Lütgehetmann, MD ^{2,3} , Johannes K
7	Knobloch, MD ^{2,3} , Julian Schulze zur Wiesch, MD ^{1,2,#} , Ansgar W Lohse, MD ^{1,2,#}
8	
9	¹ I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf,
10	Martinistraße 52, 20249 Hamburg, Germany
11	² German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems
12	³ Institute of Medical Microbiology, Virology and Hygiene, University Medical Center
13	Hamburg-Eppendorf, Martinistraße 52, 20249 Hamburg, Germany
14	[#] contributed equally
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 33 **Objective:** To assess the effectiveness of multimodal infection control interventions in the
- 34 prevention of SARS-CoV-2 infections in healthcare professionals
- 35

36 **Design**: Sequential follow-up study

37

38 Setting: Largest tertiary care centre in northern Germany

39

40 Participants: 1253 employees of the University Medical Center Hamburg-Eppendorf were 41 sequentially assessed for the presence of SARS-CoV-2 IgG antibodies at the beginning of the 42 covid-19 epidemic (20 March – 9 April), one month (20 April – 8 May), and another two 43 months later (22 June – 24 July). Of those, 1026 were healthcare workers (HCWs) of whom 44 292 were directly involved in the care of covid-19 patients. During the study period, infection 45 control interventions were deployed, those included i) strict barrier nursing of all known 46 covid-19 patients including FFP2 (N95) masks, goggles, gloves, hoods and protective gowns, 47 ii) visitor restrictions with access control at all hospital entries, iii) mandatory wearing of 48 disposable face masks in all clinical settings, and iv) universal RT-PCR admission screening of 49 patients.

50

51 Main Outcome Measures: SARS-CoV-2 IgG seroconversion rate

52

53 **Results**: At the initial screening, ten participants displayed significant IgG antibody ratios. 54 Another ten individuals showed seroconversion at the second time point one month later, 55 only two further participants seroconverted during the subsequent two months. The overall 56 SARS-CoV-2 seroprevalence in the study cohort at the last follow-up was 1.8%, the 57 seroconversion rate dropped from 0.81% to 0.08% per month despite a longer observation 58 period. Amongst HCWs seropositivity was increased in those directly involved in the care of 59 patients with SARS-CoV-2 infections (3.8%, n=11) compared to other HCWs (1.4%, n=10, 60 P=0.025). However, after the adoption of all multimodal infection control interventions 61 seroconversions were observed in only two more HCWs, neither of whom were involved in 62 inpatient care.

- **Conclusion:** Multimodal infection control and prevention interventions are highly effective in
- mitigating SARS-CoV-2 infections of healthcare professionals.

96 INTRODUCTION

97 Healthcare workers (HCWs) are at the front line of the coronavirus disease 2019 (covid-19) 98 pandemic response and disproportionally at risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to occupational exposure.^{1 2} The Chinese 99 100 ophthalmologist Li Wenliang, who was one of the first physicians to issue emergency warnings 101 about a novel viral pneumonia that was later identified as covid-19 died after being infected when caring for a pre-symptomatic patient.³ This individual case as well as larger case series 102 103 illustrate the considerable challenges of HCW protection, especially since the risk of infections 104 from pre- or asymptomatic SARS-CoV-2 infected individuals was initially often 105 underestimated.^{4 5} Protection of HCWs from infection requires not only strict application of 106 personal protective equipment (PPE), but also the prompt identification of infected 107 individuals, who may be asymptomatic or oligosymptomatic. Protection of HCWs not only 108 serves as personal protection but is also paramount to mitigate nosocomial transmission to 109 vulnerable patients and fellow HCWs. HCW infections may also lead to critical staff shortages. 110 Various infection prevention and control interventions have been adapted worldwide with 111 various efficacies, including the use of adequate PPE ⁶⁻⁸, universal admission screening of patients ^{9 10}, and RT-PCR surveillance of exposed HCWs.^{11 12} However, reports about limited 112 113 availability of sufficient PPE and high infection rates in HCWs, particularly during the early 114 phase of the outbreak, have raised concerns about whether HCWs can be adequately protected from contracting occupational infections.¹³ ¹⁴ The World Health Organization 115 recently reported that HCWs account for over 10% of overall global covid-19 cases.¹⁵ While 116 117 strict adherence to adequate PPE in areas caring for covid-19 patients is of major importance, 118 this alone may be insufficient in protecting HCWs and in preventing nosocomial infections 119 due to the infectious risk posed by as yet unidentified patients and colleagues. The aim of our 120 study was to prospectively evaluate the effectiveness of sequentially instituted multimodal 121 infection control interventions at our large tertiary care centre by sequential seroprevalence 122 measurements and assessment of seroconversion rates amongst the various hospital 123 workers.

- 124
- 125
- 126
- 127

128 METHODS

129 Study design

130 Participants were recruited in the screening period 1 (SP 1) between 20 March and 9 April 131 2020 by informing employees of the University Medical Center Hamburg-Eppendorf. The city-132 state of Hamburg with 1.8 million inhabitants and a metropolitan catchment area of more 133 than 4.5 million inhabitants was affected by the pandemic relatively early due to public 134 holidays in March 2020, when numerous travelers returned from high-risk regions, especially 135 Italian and Austrian ski resorts. By 24 July, a total of 5291 cases had been confirmed, which constitutes one of the highest rates in Germany.¹⁶ The University Medical Center Hamburg-136 137 Eppendorf, which has 1738 hospital beds, has treated more than 170 covid-19 patients during 138 the study period. Of those, 70 were admitted to the intensive care unit, 51 required 139 mechanical ventilation, and 12 patients required extracorporeal membrane oxygenation 140 (ECMO) therapy. Of note, a large number of immunocompromised patients with high viral 141 loads and a protracted course of disease posed a particularly high transmission risk to HCWs.¹⁷ 142 Participants were recruited to the study via an internal email newsletter. To assess the 143 infection rate of employees, we assessed seroconversion at one and three months: i) sampling 144 period 2 (SP 2) one month after SP 1 (20 April to 8 May 2020) and ii) sampling period 3 (SP 3) 145 another 2 months after SP 2 (22 June to 24 July).

146

147 Data collection

148 On the day of recruitment, we collected demographic and general work-related data including 149 profession, occupational area, and patient contacts using a questionnaire. In addition, we 150 used another questionnaire to assess known and possible past contact to covid-19 patients 151 with or without sufficient PPE as well as presence of symptoms during the past 4 weeks at SP 152 1 and SP 2 and during the past 8 weeks at SP 3 respectively. Fever, cough, and dyspnea were 153 classified as typical symptoms while rhinorrhea, sore throat, headache, stomach pain, joint 154 and muscle pain, nausea, and diarrhea and were considered as uncharacteristic symptoms. 155 Questionnaires were available both paper-based and via online REDcap electronic data capture tools hosted at our institution.^{18 19} Study participants with positive SARS-CoV-2 IgG 156 157 ratio were contacted again by phone to ask if nasopharyngeal swabs for RT-PCR had been 158 performed and whether a source of infection could be identified.

160 Infection control interventions

- 161 A number of infection control measures were undertaken at our institution listed in table 1.
- 162
- 163

Table 1 – Infection control interventions at the University Medical Center Hamburg-164

- 165 **Eppendorf and in Hamburg, Germany**
- 166

Interventions at the University Medical Center Hamburg-Eppendorf							
27 February	ory Opening of an on-campus covid-19 testing clinic						
11 MarchCancellation of all meetings not directly related to patient care							
18 March Mandatory wearing of face masks in the emergency department							
19 March	Implementation of visitor restrictions						
22 March Mandatory wearing of face masks in all clinical settings							
10 April	Mandatory wearing of FFP2 masks at all oncology and haematology wards						
	and clinics						
20 April	Universal RT-PCR admission screening of patients						
11 May	Universal RT-PCR screening of employees caring for covid-19 patients or						
11 Widy	vulnerable patients						
Interventions in Hamburg, Germany							
16 March	Closure of educational facilities						
22 March	Stay at home order						
27 April	Mandatory wearing of face masks						

167

168

169 As a large tertiary referral centre and one of the major infectious diseases units of the country, 170 we have highly trained personnel and a specialized infectious disease ward. In addition, 171 additional covid-19 units were opened both in intensive care and for standard care, following 172 intensive staff training. Thus, patient care with full PPE including FFP2 masks of all identified 173 covid-19 patients was standard of care from the beginning of the pandemic, and even though 174 supply was scarce throughout the first two months, application of strict protocols to limit 175 wasteful use of equipment allowed sufficient supply all through the pandemic. When first

176 infections in staff members occurred, several further steps were undertaken starting with the universal use of face masks in all clinical settings, and measures were intensified further after 177 178 a nosocomial outbreak on one of the haematology wards.¹⁷ In addition to separate covid-19 179 units, use of full PPE in all covid-19 care, and use of surgical face masks in all clinical units of 180 the hospital, universal screening of all hospital admissions was instituted at April 20, with a 181 roll-out period of about ten days until full adherence across all hospital departments. In 182 addition, RT-PCR testing of staff at risk was offered as of May 11, but this measure was 183 primarily instituted as a reassurance measure for our staff rather than an infection control 184 measure.

185

186 Study procedures

187 During all three sampling periods, serum samples were drawn from the study participants. A 188 semi-quantitative SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) targeting the 189 S1-Domain of the S-protein spike protein subunit was performed using a commercial kit 190 (Euroimmun Medizinische Labordiagnostika, Lübeck, Germany). Testing procedures were 191 performed according to the manufacturer's instructions. According to the manufacturer, a 192 ratio of \geq 1.1 should be regarded as positive. The manufacturer reports a specificity of 99.3%. 193 We have recently independently validated those results and showed a specificity of 99.1%.²⁰ 194 However, an optimized IgG ratio of \geq 1.5, has been shown to display a specificity of 100% by 195 us and by others.²¹ Therefore, we used both the manufacturer's and this more stringent cut-196 off value for positive results to account for optimal specificity in a low prevalence 197 environment. Given the sequential testing in our study population and the expected rise of 198 IgG antibody ratio \geq 1.5 at some time point in infected individuals, this cut-off value is 199 considered the best compromise for optimum sensitivity and specificity. Study participants 200 were classified as seropositive in all future sampling periods, if they had an IgG antibody ratio 201 ≥1.5 at least once, even if antibody ratios waned over time. This was found to be the case in 202 three study participants, who became seronegative at SP 3. However, in order to also look at 203 the data with maximum sensitivity, we also analyzed the participants with a ratio of >1.1.

- 204
- 205
- 206
- 207

Statistical analyses

- Results were subjected to statistical analysis using SPSS 20.0 (IBM, Armonk, NY, USA). Fishers'
- exact test was used to the determine association between two categorical variables. A two-
- sided P value less than 0.05 was considered significant.

Patient and public involvement

- The study was presented to and approved by the academic and non-academic workers
- representation boards of our hospital and the design agreed with both boards as well as the
- management board of the hospital.
- RESULTS
- Study population
- A total of 1253 individuals were included during SP 1, which represent around 11% of all employees at our centre (table 2).

240 Table 2 - Characterization of the study population

n	1253				
Sex, n (%)					
Female	934 (74.5)				
Male	308 (24.6)				
Diverse	11 (0.9)				
Age					
Range, years	16-69				
Mean, years	38.4				
Occupation, n (%)					
HCW	1026 (81.9)				
Category					
- Nurse	444 (35.4)				
- Physician	275 (21.9)				
- Medical technician	105 (8.4)				
- Medical student	73 (5.8)				
- Physiotherapist	15 (1.2)				
- Other	114 (9.1)				
Location					
- Regular ward	332 (26.5)				
- Outpatient clinic	234 (18.7)				
- Intensive care unit	130 (10.4)				
- Operating room	111 (8.9)				
- Emergency department	63 (5.0)				
- Other	156 (12.5)				
Non-HCW	227 (18.1)				

241

242

243 All study participants participated at the second follow up visit, but 23 (1.8%) missed the first 244 follow-up visit. The average age of the study cohort was 38.4 years; 934 were women and 308

245 were men. The majority of participants (n=1026, 81.9%) were HCWs such as nurses (n=444,

246 35.4%), medical doctors (n=275, 21.9%), medical technicians with regular patient contact (n=105, 8.4%) and physiotherapists (n=15, 1.2%). Altogether, the participants well 247 248 represented the average workforce of our centre, consisting of 30.1% nurses, 25.8% medical 249 doctors, and 44.1% other staff members, with a somewhat higher proportion of front-line 250 HCWs in the study. Study participants were recruited from all occupational areas of our 251 hospital including regular wards (n=332, 26.5%), outpatient clinics (n=234, 18.7%), the 252 intensive care unit (n=130, 10.4%) and the emergency department (n=63, 5.0%). The remainder of 227 (18.1%) participants not classified as HCWs were research scientists, 253 254 administrative staff or belonged to other occupational groups not directly involved in patient 255 care. Information on contact with covid-19 was provided by 1253 individuals at SP 1, 1169 256 individuals at SP 2, and 1110 individuals at SP 3 (table 3).

257

Table 3 - Occupational exposure of the study population

	Seronegative	Seropositive SP 1	Seroconversion SP 2	Seroconversion SP 3			
n	1231	10	10	2			
Occupation, n (%)							
HCW	1005 (81.6)	9 (90.0)	10 (100)	2 (100)			
- Nurse	434 (40.0)	6 (60.0)	4 (40.0)	0 (0)			
- Physician	266 (22.4)	2 (20.0)	5 (50.0)	2 (100)			
- Other	305 (23.2)	0 (0)	1 (10.0)	0 (0)			
Non-HCW	226 (22.5)	1 (10.0)	0	0 (0)			
Contact to covid-19 cases, n (%)							
Total	405 (32.9)	6 (60.0)	9 (90.0)	2 (100)			
Patients	281 (22.8)	3 (30.0)	6 (60.0)	2 (100)			
- only with PPE	218 (17.7)	2 (20.0)	2 (20.0)	1 (50.0)			
- without PPE	63 (5.1)	1 (10.0)	4 (40.0)	1 (50.0)			
Colleagues	137 (11.3)	2 (20.0)	1 (10.0)	0 (0)			
Community	31 (2.5)	1 (10.0)	3 (30.0)	0 (0)			

259

A total of 23.3% (n=292) of participants reported having been in contact with known covid-19 patients. The majority of those (n=223) worked exclusively in the direct care of patients with diagnosed SARS-CoV-2 infections and thus reported to always be equipped with appropriate PPE. Another 69 HCWs had contact with patients that were diagnosed with covid-19 only later, i.e. after exposure, and did therefore not wear adequate PPE at the time. Occupational contact to infected colleagues was reported by 11.2% (n=140), and known community contacts by 2.8% (n=35) of participants.

268

269 Serological results

270 At the initial screening period a total of 0.8% (n=10, 95% confidence interval [CI] 0.3 to 1.3) participants were found to be SARS-CoV-2 seropositive (figure 1). Another ten individuals, 271 272 representing 0.8% of all study participants at SP 2, showed seroconversion at the first follow-273 up visit, giving a seroprevalence of 1.6% (95% CI 0.9 to 2.3). At SP 3, two more individuals had 274 developed SARS-CoV-2 IgG antibodies, giving a seroconversion rate of 0.16% between SP 2 275 and SP 3, or 0.08% per month, and thus a total seroprevalence of 1.8% (n=22, 95% CI 1.0 to 276 2.5) by the end of the study when using the optimized IgG ratio of \geq 1.5. One of the two 277 participants showing seroconversion only at SP 3 had indeed a positive RT-PCR for SARS-CoV-278 2 and missed the first follow-up visit since he was in guarantine. While it is likely that that this 279 seroconversion took place before SP 2, we have no proof of this, thus the case was counted 280 as converting in the second observation period.

281 Three participants with an IgG ratio of \geq 1.5 at SP 1 subsequently had a negative test result at 282 SP 2 and SP 3 respectively suggesting that their infection had occurred early. This 283 demonstrates that a cross-sectional study with a single measurement only at SP 3 would have 284 missed these three infections. When analyzing the serological data with of maximum 285 sensitivity, i.e. with a cut-off value of \geq 1.1, the overall results were very similar: 19 286 participants showed anti-SARS-CoV2 antibodies with a ratio \geq 1.1 at SP 1, another 13 287 participants showed seroconversion during the first month between SP 1 and SP 2. Only 2 288 additional participants showed seroconversion with this lower cut-off in the subsequent two 289 months, bringing the total of possible seroconverters in the last two months up to four, or 290 two per month (figure 2).

291

. . .

293 RT-PCR testing history of seroconverted participants

Out of all clearly seropositive study participants, a total of 40.9% (n=9), one of them before SP 1 and the others between SP 1 and SP 2, had been diagnosed with covid-19 by RT-PCR and thus had been placed under quarantine during the study period. Another six seropositive HCWs reported that they had at least one nasopharyngeal swab performed due to symptoms or close contact with a covid-19 case but were tested negative at that time. The remainder of seven clearly seropositive individuals had not been tested by RT-PCR at all.

300

301 Risk factors for seroconversion

302 Complete information on symptoms throughout the study period was provided by 1061 303 (84.7%) of the study participants. Of those, 54.9% (n=582) reported covid-19 related 304 symptoms (see supplementary table). Only 10.6% (n=112) did not report any symptoms 305 throughout the study period, the rest reported symptoms not considered typical for covid-306 19. Typical SARS-CoV-2 symptoms were reported by 72.7% (n=16) of seropositive and 54.4% 307 (n=566) of seronegative study participants (P=0.4). The probable source of infection could be 308 identified for the majority of seropositive study participants. A total of six HCWs presumably 309 got infected when caring for patients that were only subsequently diagnosed with covid-19 and had thus not used appropriate PPE at the time of exposure. Five HCWs most likely 310 311 contracted SARS-CoV-2 while caring for covid-19 patients with adequate PPE. Other probable 312 infection routes in our cohort were close contact with infected colleagues (n=3), community 313 transmission in high-risk regions (n=3), and infected household contacts (n=1). For the 314 remainder of four seropositive employees, the source of infection could not be established. 315 Seropositivity was not statistically significantly higher in HCWs (2.0%, n=21/1026) compared 316 to other hospital workers (0.4%, n=1/227, P=0.16). When only addressing HCWs directly 317 involved in the care of patients with SARS-CoV-2 infections (3.8%, n=11/292) compared to 318 other HCWs (1.4%, n=10/734, P=0.025) seropositivity was significantly increased. 319 Importantly, both seroconverters of SP3 were not involved in inpatient care, but exclusively 320 worked in the outpatient clinics.

321

322 **DISCUSSION**

This study demonstrates a very low overall SARS-CoV-2 seroprevalence in hospital workers at
 our tertiary care centre, and the increasing effectiveness of a combination of infection control

325 measures. The low overall in-hospital SARS-CoV-2 transmission rates of healthcare personnel were achieved despite both substantial community transmission in the city-state of Hamburg,

327 and, more importantly, a large number of covid-19 patients treated, some with very high and 328 long-lasting viral loads, at our tertiary care centre. While the relatively early detection of the first cases in Germany ²² may have increased preparedness, the addition of further 329 330 multimodal infection prevention and control measures was instrumental in minimizing 331 occupational exposure risks. While seropositivity amongst HCWs was initially higher in HCWs 332 directly involved in the care of patients with SARS-CoV-2 infections compared to other 333 employees, only two more seroconversions were observed after the implementation of all 334 multimodal infection during the last two months, and both of these did not involve inpatient 335 care but seemed to have occurred during outpatient clinics or from the community. Also, one 336 of those two physicians had been tested positive for SARS-CoV-2 by RT-PCR between SP 1 and 337 SP 2 and did therefore not attend the first follow-up visit, so that this seroconversion may 338 also have also occurred the first observation period. Thus, presumably only one study 339 participant, a physician employed in an outpatient clinic, contracted a SARS-CoV-2 infection 340 in the two months between SP 2 and SP 3. All other participants were protected despite a 341 considerable number of covid-19 patients being treated at our centre during that time period 342 (figure 3). Considerably higher seroprevalence has been reported for HCWs in Belgium (6,4 -343 12,6%) ^{23 24}, Spain (11 – 31,6%) ^{25 26}, the United Kingdom (24 - 43.5%) ^{27 28} and the United States of America (7,6 - 36%)^{29 30}. Those high infection rates are likely to be at least partially 344 345 attributable to insufficient protection of exposed HCWs. While the effectiveness of universal 346 use of face masks at hospitals has been shown to significantly decrease hospital transmission 347 ⁶⁷, shortages of appropriate PPE for HCWs in many hospitals have emerged particularly during 348 the early phase of the pandemic. However, adequate PPE when caring for confirmed covid-349 19 patients alone is not sufficient to prevent healthcare transmission, since asymptomatic 350 and pre-symptomatic individuals can play a pivotal role in the transmission of SARS-CoV-2.4 351 Also at our centre, the repeated detection of SARS-CoV-2 positive yet asymptomatic patients 352 presented an important exposure risk leading to occupational infections. Systematic RT-PCT 353 testing of all hospital admissions, either prior to scheduled admissions or in the emergency 354 department, instituted at the end of April, reduced this infection risk to practically zero. The fact that three HCWs seroconverted during the study period despite reporting use of 355 356 appropriate PPE when caring for covid-19 patients underlines that PPE alone is not sufficient

357 to prevent viral transmission to HCWs. To our surprise, the majority of seropositive study 358 participants had not been diagnosed with SARS-CoV-2 infections despite a very low threshold 359 in our hospital for RT-PCR screening, with more than 7.300 nasopharyngeal swab 360 examinations of hospital HCWs performed during the study period. Furthermore, symptoms 361 compatible with covid-19 were widely prevalent in healthcare professionals regardless of 362 serological results, a number of seropositive employees did not report any such symptoms 363 and were thus not tested. This demonstrates that symptom-based testing of HCWs, while an 364 important tool to mitigate nosocomial infections, has limited sensitivity and very low 365 specificity in detecting infected HCWs. Complete protection of HCWs is not only helpful for 366 their direct protection but is also key for preventing nosocomial infections in patients.

367

368 Limitations

369 There are some limitations to our study: firstly, we did not recruit a strictly representative 370 sample of healthcare professionals at our institution, since participation was voluntary. 371 However, the distribution of professions was close to the overall hospital workforce 372 distribution. We included a somewhat higher proportion of clinically exposed HCWs, in 373 particular front-line HCWs from the emergency department, intensive care and infectious 374 diseases departments, most likely because these HCWs were highly exposed and thus more 375 motivated to participate in the study. Secondly, since several multimodal infection control 376 interventions were sequentially adopted and the study did not include a control group, this 377 study is not able to answer the question which measures are most effective in preventing 378 healthcare transmission, and which might have been superfluous. Thirdly, sensitivity and 379 specificity of serological assays is limited, so a precise assessment of the number of infected 380 HCWs is not possible. However, the results were independent of the cut-off levels used for 381 serological testing (figure 2), supporting the reliability of the results.

382

383 Conclusion

We report a very low seroprevalence amongst HCWs and other healthcare professionals at our tertiary care centre at the beginning of the covid-19 epidemic and very few seroconversions after the implementation of multimodal infection prevention and control interventions. When in addition to personal protection and universal face masks RT-PCR screening of hospital admissions was instituted, occupational transmission could be brought

389 down to zero cases in inpatient care and only one or two related to outpatient clinics. Taken 390 together, our findings demonstrate that multimodal infection control measures are able to 391 effectively prevent healthcare transmission for SARS-CoV-2, and thus protect both HCWs and 392 patients.

393

394 Contributors

395 TTB, DS, JSzW, and AWL contributed equally to this paper. TTB, DS, JSzW, and AWL conceived 396 and designed the study. TTB, SL, VS, JK, MT, and FU contributed to recruitment of healthcare 397 professionals, data collection and data analysis. DS, ML and JKK contributed to literature 398 search, data collection and data analysis. TTB and DS contributed to data visualization. SH, SS, 399 MMA, ML, and JKK contributed to data interpretation. TTB, JSzW, and AWL drafted the 400 manuscript. DS, SH, SS and ML reviewed and edited the manuscript. TTB, DS, JSzW, and AWL 401 are the guarantors. The corresponding author attests that all listed authors meet authorship 402 criteria and that no others meeting the criteria have been omitted

403

404 Transparency declaration

The guarantors affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

409

410 Funding

411 The authors received no external funding for this work.

412

413 **Competing interests**

414 All authors have completed the ICMJE uniform disclosure form at 415 www.icmje.org/coi disclosure.pdf and declare: AWL had a material transfer agreement with 416 Euroimmun GmbH, which included ten ELISA plates as well as technical help provided by the 417 company when setting up the newly established ELISA. All other authors declare no support 418 from any organisation for the submitted work. All authors declare no financial relationships 419 with any organisations that might have an interest in the submitted work in the previous three

420 years; no other relationships or activities that could appear to have influenced the submitted

- 421 work.
- 422

423 Ethical approval

The study protocol was reviewed and approved by the Ethics Committee of the Medical
Council of Hamburg (PV 7298). Written informed consent was obtained by all study
participants prior to enrolment.

427

428 Dissemination to participants and related patient and public communities

429 The findings of this study will be disseminated to all departments of the University Medical

- 430 Center Hamburg-Eppendorf and to all employees of our institution via an internal newsletter.
- 431

432 Acknowledgments

- 433 We thank all study participants and departments of the University Medical Centre Hamburg-
- 434 Eppendorf for active participation in the study. We thank Sabrina Kreß, Jennifer Wigger,
- 435 Martina Schulz, Corinna Eggers, Angelika Schmidt, Silke Kummer, Robin Woost, Nils
 436 Dittberner, and Marcus Wurlitzer for excellent technical assistance.
- 437

438 Data sharing

- 439 No additional data available.
- 440

441 **References**

- 442 1. Zhan M, Qin Y, Xue X, et al. Death from Covid-19 of 23 Health Care Workers in China. *N*443 *Engl J Med* 2020 doi: 10.1056/NEJMc2005696
- 444 2. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? *Lancet* 2020;395(10231):1225-28.
- 445 doi: 10.1016/s0140-6736(20)30627-9
- 446 3. Petersen E, Hui D, Hamer DH, et al. Li Wenliang, a face to the frontline healthcare worker.
- 447 The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak.
- 448 Int J Infect Dis 2020;93:205-07. doi: 10.1016/j.ijid.2020.02.052
- 449 4. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and
- 450 Transmission in a Skilled Nursing Facility. *N Engl J Med* 2020;382(22):2081-2090. doi:
- 451 10.1056/NEJMoa2008457

452 5. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current 453 Strategies to Control Covid-19. N Engl J Med 2020 doi: 10.1056/NEJMe2009758 454 6. Liu M, Cheng SZ, Xu KW, et al. Use of personal protective equipment against coronavirus 455 disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. 456 *BMJ* 2020;369:m2195. doi: 10.1136/bmj.m2195 457 7. Wang X, Ferro EG, Zhou G, et al. Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. JAMA 2020 doi: 458 459 10.1001/jama.2020.12897 460 8. Pan A, Liu L, Wang C, et al. Association of Public Health Interventions With the 461 Epidemiology of the COVID-19 Outbreak in Wuhan, China. JAMA 2020;323(19):1-9. 462 doi: 10.1001/jama.2020.6130 463 9. Sutton D, Fuchs K, D'Alton M, et al. Universal Screening for SARS-CoV-2 in Women 464 Admitted for Delivery. N Engl J Med 2020;382(22):2163-64. doi: 465 10.1056/NEJMc2009316 466 10. Al-Shamsi HO, Coomes EA, Alrawi S. Screening for COVID-19 in Asymptomatic Patients 467 With Cancer in a Hospital in the United Arab Emirates. JAMA Oncol 2020 doi: 468 10.1001/jamaoncol.2020.2548 469 11. Treibel TA, Manisty C, Burton M, et al. COVID-19: PCR screening of asymptomatic health-470 care workers at London hospital. The Lancet 2020 doi: 10.1016/s0140-471 6736(20)31100-4 472 12. Black JRM, Bailey C, Przewrocka J, et al. COVID-19: the case for health-care worker 473 screening to prevent hospital transmission. Lancet 2020;395(10234):1418-20. doi: 474 10.1016/s0140-6736(20)30917-x 475 13. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators and 476 Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med 477 2020;382(18):e41. doi: 10.1056/NEJMp2006141 478 14. Wang J, Zhou M, Liu F. Reasons for healthcare workers becoming infected with novel 479 coronavirus disease 2019 (COVID-19) in China. J Hosp Infect 2020;105(1):100-01. doi: 480 10.1016/j.jhin.2020.03.002 481 15. World Health Organization (WHO) Coronavirus disease (COVID-2019) press briefings. 482 https://www.who.int/docs/default-source/coronaviruse/transcripts/covid-19-483 virtual-press-conference---17-july.pdf?sfvrsn=dd7f91a1 0 [Accessed on 29 July 2020]

484 16. Robert Koch Institute. Coronavirus Disease 2019 (COVID-19) Daily Situation Report of
485 the Robert Koch Institute.

486 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte

487 /2020-07-27-en.pdf?__blob=publicationFile [Accessed on 29 July 2020]

- 488 17. Weisel KC, Morgner-Miehlke A, Petersen C, et al. Implications of SARS-CoV-2 Infection
- 489 and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center
 490 Hamburg. *Oncol Res Treat* 2020;43(6):307-13. doi: 10.1159/000508272
- 491 18. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a
- 492 metadata-driven methodology and workflow process for providing translational
- 493 research informatics support. *J Biomed Inform* 2009;42(2):377-81. doi:
- 494 10.1016/j.jbi.2008.08.010
- 495 19. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international

496 community of software platform partners. *J Biomed Inform* 2019;95:103208. doi:
 497 10.1016/j.jbi.2019.103208


20. Pflüger LS, Bannasch JH, Brehm TT, et al. Clinical evaluation of five different automated
SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. *J Clin Virol*2020:104549. doi: 10.1016/j.jcv.2020.104549

501 21. Meyer B, Torriani G, Yerly S, et al. Validation of a commercially available SARS-CoV-2


- 502 serological Immunoassay. *medRxiv* 2020:2020.05.02.20080879. doi:
- 503 10.1101/2020.05.02.20080879
- 504 22. Stafford N. Covid-19: Why Germany's case fatality rate seems so low. *BMJ*505 2020;369:m1395. doi: 10.1136/bmj.m1395
- 506 23. Steensels D, Oris E, Coninx L, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in
 507 3056 Staff in a Tertiary Center in Belgium. *JAMA* 2020 doi: 10.1001/jama.2020.11160
- 508 24. Martin C, Montesinos I, Dauby N, et al. Dynamic of SARS-CoV-2 RT-PCR positivity and
- seroprevalence among high-risk health care workers and hospital staff. *J Hosp Infect*2020 doi: 10.1016/j.jhin.2020.06.028
- 511 25. Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against
- 512 SARS-CoV-2 among health care workers in a large Spanish reference hospital.
- 513 *medRxiv* 2020:2020.04.27.20082289. doi: 10.1101/2020.04.27.20082289

26. Galan I, Velasco M, Casas ML, et al. SARS-CoV-2 seroprevalence among all workers in a teaching hospital in spain: unmasking the risk. *medRxiv* 2020:2020.05.29.20116731. doi: 10.1101/2020.05.29.20116731 27. Houlihan C, Vora N, Byrne T, et al. SARS-CoV-2 virus and antibodies in front-line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study. medRxiv 2020:2020.06.08.20120584. doi: 10.1101/2020.06.08.20120584 28. Shields AM, Faustini SE, Perez-Toledo M, et al. SARS-CoV-2 seroconversion in health care workers. medRxiv 2020:2020.05.18.20105197. doi: 10.1101/2020.05.18.20105197 29. Mansour M, Leven E, Muellers K, et al. Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City. J Gen Intern Med 2020:1-2. doi: 10.1007/s11606-020-05926-8 30. Stubblefield WB, Talbot HK, Feldstein L, et al. Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for COVID-19 Patients - Nashville, Tennessee. Clin Infect Dis 2020 doi: 10.1093/cid/ciaa936






567 Figure 2 – Seroconversion rates in study participants using different cut-off ratios



- 583
- 584
- 585

586 Figure 3 - Timeline of the covid-19 epidemic at the University Medical Center Hamburg-

Eppendorf and in Hamburg, Germany.



589 Grey bars represent the number of covid-19 patients hospitalized at the University Medical 590 Center Hamburg-Eppendorf (UKE) on the respective days. The blue line represents the 591 cumulative covid-19 incidence in the 11.348 employees of the UKE detected by the low 592 threshold contact- and symptom-based RT-PCR screening. The seroprevalence in the study 593 cohort at the respective sampling periods is represented by blue squares with error bars for 594 95% confidence intervals.

606 Supplementary table – Symptoms reported by seropositive and -negative study participants

607

	Total (n=1061)	Seropositive (n=22)	Seronegative (n=1041)
Any symptoms, n(%)	949 (89.4)	20 (90.9)	929 (89.1)
Typical symptoms, n(%)	582 (54.9)	16 (72.7)	566 (54.4)
Fever, n(%)	112 (10.6)	8 (36.4)	104 (1.0)
Cough, n(%)	498 (46.9)	11 (50.0)	487 (46.8)
Dyspnea, n(%)	231 (21.8)	9 (40.9)	222 (21.3)
Rhinorrhea, n(%)	717 (67.7)	17 (77.3)	700 (67.2)
Sore throat, n(%)	560 (52.8)	11 (50.0)	549 (52.7)
Headache, n(%)	704 (66.4)	16 (72.7)	688 (66.1)
Abdominal pain, n(%)	295 (27.8)	8 (36.4)	287 (27.6)
Muscle aches, n(%)	244 (23.0)	13 (59.1)	231 (22.2)
Nausea, n(%)	213 (20.1)	8 (36.4)	205 (19.7)
Diarrhea, n(%)	296 (27.9)	8 (36.4)	288 (27.7)

608

609 Respective symptoms as stated by the study participants at SP 1 or SP 2 for the preceding

610 month and at SP 3 for the preceding 2 months. Complete information was provided by a total

611 of 1061 participants.